Gyros - News

Uppsala, Sweden, 7 December 2011

Gyros expands commercial reach in Asia

South Korea joins global biopharmaceutical community in using Gyros immunoassay platform

Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that Binex Co., Ltd., a leading CDMO (Contract Development & Manufacturing Organization) for biotechnology products in the Asian-Pacific region, has purchased a Gyrolab™ workstation.

Uppsala, Sweden, 20 October 2011

Gyros announces changes to its management team

Dr. Jon-Sverre Schanche becomes Chief Technology Officer and Vice President Technical Affairs

Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, today announced the appointment of Dr. Jon-Sverre Schanche as Chief Technology Officer and Vice President Technical Affairs. Dr. Schanche’s appointment comes as Nils Kristensen, COO and VP Technical Operations, and Stephan Hoffmann, VP Business Development, leave the company.

Uppsala, Sweden, 11 October 2011

Gyros introduces new application to monitor anti-drug antibodies during development of biotherapeutics

Automated, drug-tolerant immunoassay increases workflow efficiency

Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today the launch of a new Gyrolab™ application to increase efficiency when looking for anti-drug antibodies (ADA) during the development of biotherapeutics.

Uppsala, Sweden and Chalfont St Giles, UK, 26 August 2011

Gyros and GE Healthcare Life Sciences expand Asian distribution relationship to China, Taiwan and Hong Kong

Brings the Gyros nanoliter-scale immunoassay platform to biopharmaceutical and vaccine manufacturers in key growth markets

Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong.

Uppsala, Sweden, 3 August 2011

Gyros completes next stage of development program with expansion of product portfolio

Company announces availability of software modules and services to strengthen support for scientists using the Gyros immunoassay platform in regulated environments

Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today the completion of a development program initiated to fulfill the requirements of scientists using the Company’s immunoassay platform in the biopharmaceutical industry.

News

Immunoassays in the biotherapeutic workflow

Gyros immunoassay platform

Develop and run immunoassays at nanoliter scale:

Ready to use on Gyrolab xP workstation

Designed for use with Gyrolab CDs

E-mail:
Password:
Remember me